申请人:Sterling Drug Inc.
公开号:US04007271A1
公开(公告)日:1977-02-08
Mono-, di- or tri-(X,Y-substituted-benzoyl) esters of 1,8,9-trihydroxyanthracene, wherein the anthracene moiety can be substituted by methyl at the 3-position, X is halogen, hydroxy, nitro, lower-alkyl, lower-alkoxy, phenoxy, trifluoromethyl, lower-alkylcarboxy or lower-alkoxycarbonyl and Y is hydrogen or has the meaning given hereinabove for X, are prepared by reacting the appropriate 1,8,9-trihydroxyanthracene with the appropriate substituted-benzoic acid or functional derivative thereof, e.g., acid chloride, in an inert solvent, in the presence of a suitable basic catalyst, e.g., pyridine or triethylamine, and under an inert atmosphere. Pharmaceutical compositions comprising these esters are useful in treating dermatological conditions such as psoriasis and have the improvements of having substantially no undesirable staining and irritating properties.
1,8,9-三羟基蒽醌的单取代、双取代或三取代苯甲酰酯,其中蒽醌基团可以在3位被甲基取代,X为卤素、羟基、硝基、低烷基、低烷氧基、苯氧基、三氟甲基、低烷基羧基或低烷氧羰基,Y为氢或具有与X上述相同的含义,通过将适当的1,8,9-三羟基蒽醌与适当的取代苯甲酸或其官能衍生物(如酸氯)在惰性溶剂中,在适当的碱性催化剂(如吡啶或三乙胺)存在下,以及在惰性气氛下反应制备而成。包含这些酯的药物组合物可用于治疗诸如银屑病等皮肤病,并具有几乎没有不良染色和刺激性特性的改进。